5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Myelosuppression O
: O
ISTODAX O
can O
cause O
thrombocytopenia O
, O
leukopenia O
( O
neutropenia O
and O
lymphopenia O
) O
, O
and O
anemia O
; O
monitor O
blood O
counts O
during O
treatment O
with O
ISTODAX O
; O
interrupt O
and/or O
modify O
the O
dose O
as O
necessary O
( O
2.2 O
) O
. O

* O
Infections O
: O
Fatal O
and O
serious O
infections O
. O

Reactivation O
of O
DNA O
viruses O
( O
Epstein O
Barr O
and O
hepatitis O
B O
) O
. O

Consider O
monitoring O
and O
prophylaxis O
in O
patients O
with O
evidence O
of O
prior O
hepatitis O
B O
( O
5.2 O
) O
. O

* O
Electrocardiographic O
( O
ECG O
) O
changes O
: O
Consider O
cardiovascular O
monitoring O
in O
patients O
with O
congenital O
long O
QT O
syndrome O
, O
a O
history O
of O
significant O
cardiovascular O
disease O
, O
and O
patients O
taking O
medicinal O
products O
that O
lead O
to O
significant O
QT O
prolongation O
. O

Ensure O
that O
potassium O
and O
magnesium O
are O
within O
the O
normal O
range O
before O
administration O
of O
ISTODAX O
( O
5.3 O
) O
. O

* O
Tumor O
lysis O
syndrome O
: O
Patients O
with O
advanced O
stage O
disease O
and/or O
high O
tumor O
burden O
are O
at O
greater O
risk O
and O
should O
be O
closely O
monitored O
and O
appropriate O
precautions O
taken O
( O
5.4 O
) O
. O

* O
Embryo-fetal O
toxicity O
: O
ISTODAX O
may O
cause O
fetal O
harm O
when O
administered O
to O
a O
pregnant O
woman O
. O

Advise O
women O
of O
potential O
hazard O
to O
the O
fetus O
and O
to O
avoid O
pregnancy O
while O
receiving O
ISTODAX O
( O
5.5 O
, O
8.1 O
) O
. O

5.1 O
Myelosuppression B-OSE_Labeled_AE
Treatment O
with O
ISTODAX O
can O
cause O
thrombocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
( O
neutropenia B-OSE_Labeled_AE
and O
lymphopenia B-OSE_Labeled_AE
) O
, O
and O
anemia B-OSE_Labeled_AE
. O

Monitor O
blood O
counts O
regularly O
during O
treatment O
with O
ISTODAX O
, O
and O
modify O
the O
dose O
as O
necessary O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.2 O
Infections O
Fatal B-NonOSE_AE
and O
serious O
infections B-OSE_Labeled_AE
, O
including O
pneumonia B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
and O
viral B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
including O
Epstein O
Barr O
and O
hepatitis O
B O
viruses O
, O
have O
been O
reported O
in O
clinical O
trials O
with O
ISTODAX O
. O

These O
can O
occur O
during O
treatment O
and O
within O
30 O
days O
after O
treatment O
. O

The O
risk O
of O
life O
threatening O
infections O
may O
be O
greater O
in O
patients O
with O
a O
history O
of O
prior O
treatment O
with O
monoclonal O
antibodies O
directed O
against O
lymphocyte O
antigens O
and O
in O
patients O
with O
disease B-Not_AE_Candidate
involvement I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
bone I-Not_AE_Candidate
marrow I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
has O
occurred O
in O
1 O
% O
of O
PTCL B-Not_AE_Candidate
patients O
in O
clinical O
trials O
in O
Western O
populations O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

In O
patients O
with O
evidence O
of O
prior O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
consider O
monitoring O
for O
reactivation O
, O
and O
consider O
antiviral O
prophylaxis O
. O

Reactivation B-OSE_Labeled_AE
of O
Epstein I-OSE_Labeled_AE
Barr I-OSE_Labeled_AE
viral I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
leading O
to O
liver B-NonOSE_AE
failure I-NonOSE_AE
has O
occurred O
in O
a O
trial O
of O
patients O
with O
relapsed O
or O
refractory O
extranodal O
NK/ O
T B-Not_AE_Candidate
- I-Not_AE_Candidate
cell I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
. O

In O
one O
case O
, O
ganciclovir O
prophylaxis O
failed O
to O
prevent O
Epstein B-NonOSE_AE
Barr I-NonOSE_AE
viral I-NonOSE_AE
reactivation I-NonOSE_AE
. O

5.3 O
Electrocardiographic O
Changes O
Several O
treatment-emergent O
morphological O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ECGs I-OSE_Labeled_AE
( O
including O
T B-OSE_Labeled_AE
- I-OSE_Labeled_AE
wave I-OSE_Labeled_AE
and O
ST-segment O
changes I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
clinical O
studies O
. O

The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

In O
patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
patients O
with O
a O
history O
of O
significant O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
patients O
taking O
anti-arrhythmic O
medicines O
or O
medicinal O
products O
that O
lead O
to O
significant O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
, O
consider O
cardiovascular O
monitoring O
of O
ECGs O
at O
baseline O
and O
periodically O
during O
treatment O
. O

Confirm O
that O
potassium O
and O
magnesium O
levels O
are O
within O
normal O
range O
before O
administration O
of O
ISTODAX O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.4 O
Tumor O
Lysis O
Syndrome O
Tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TLS I-OSE_Labeled_AE
) O
has O
been O
reported O
to O
occur O
in O
1 O
% O
of O
patients O
with O
tumor B-Not_AE_Candidate
stage O
CTCL B-Not_AE_Candidate
and O
2 O
% O
of O
patients O
with O
Stage O
III/IV O
PTCL B-Not_AE_Candidate
. O

Patients O
with O
advanced O
stage O
disease O
and/or O
high O
tumor B-Not_AE_Candidate
burden O
may O
be O
at O
greater O
risk O
, O
should O
be O
closely O
monitored O
, O
and O
managed O
as O
appropriate O
. O

5.5 O
Use O
in O
Pregnancy O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
ISTODAX O
in O
pregnant B-Not_AE_Candidate
women O
. O

However O
, O
based O
on O
its O
mechanism O
of O
action O
and O
findings O
in O
animals O
, O
ISTODAX O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

In O
an O
animal O
reproductive O
study O
, O
romidepsin O
was O
embryocidal B-NonOSE_AE
and O
resulted O
in O
adverse O
effects B-NonOSE_AE
on I-NonOSE_AE
the I-NonOSE_AE
developing I-NonOSE_AE
fetus I-NonOSE_AE
at O
exposures O
below O
those O
in O
patients O
at O
the O
recommended O
dose O
of O
14 O
mg/m O
2 O
/week O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
ISTODAX O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

